recast-jats-buildd8e1462159jitcJ Immunother CancerjitcJournal for ImmunoTherapy of CancerJ Immunother CancerJ Immunother Cancer2051-1426BMJ Publishing Group Ltdjitc-2020-0796-5corr110.1136/jitc-2020-0796-5corr1/jitc/8/1/e0796-5corr1.atomCorrectionOpen accessSpecial collectionsOpen accessCorrection: A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer520201452020201220192012201981e0796-5corr1© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.2020http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.special-featureunlocked

Rammensee H, Wiesmüller K, Chandran PA, et al. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. J Immuno Ther Cancer 2019;7:307. doi: 10.1186/s40425-019-0796-5.

In the article titled ‘A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer’, the author name Yamel Cardona Gloria is abbreviated incorrectly. The author’s first name is Yamel and the family name is Cardona Gloria. The correct abbreviation is Cardona Gloria Y.